Benefit of Alzheimer's Drug in Clinical Trials in Doubt
July 20 (Bloomberg) -- The leading Alzheimer’s drug discovery strategy being pursued by companies including Wyeth and Elan Corp. appears increasingly risky as new studies emerge.
More than a dozen drugs now in human testing were designed to slow progression of the illness by blocking the proteins that form clumps in the brain. While the medicines may reduce the levels of this substance, they have shown little sustained ability to improve memory or mental function. And a more complex picture is emerging from laboratories: the beta amyloid protein that scientists think kills neurons isn’t always bad.
Read More:
Original Article
http://www.bloomberg.com/apps/news?pid=20601085&sid=aHIDqOAHPeH4